Month: April 2025

Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including one late-breaker, have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7 – 10, 2025 in Amsterdam, Netherlands. The following abstracts will be presented as posters in the Viral Hepatitis B and D: New Therapies, Unapproved Therapies or Strategies session on May 8, 2025, from 8:30 am – 5:00 pm CET. Abstract Number: 1768Title: IM-PROVE I: characterization of chronic hepatitis B (CHB) subjects with functional cure or HBV DNA suppression after completion of imdusiran...

2025 First Quarter SalesPress release – Paris, April 23, 2025, at 7:30am CEST Strong start to the year,demonstrating the relevance of our health-oriented portfolioStrong Q1 2025, with sales of €6,844m, up +4.3% on a like-for-like (LFL) basis Contributions from both volume/mix (+1.9%) and price (+2.4%); positive volume/mix again in all categories Broad-based growth, demonstrating the resilience of our businessVery strong performance in China, North Asia & Oceania, in all categories Solid growth in North America, led by a continued, winning momentum in High Protein Consistent progress in Europe with solid volume/mix2025 guidance confirmed, in line with mid-term ambition: LFL sales growth expected between +3% and +5%, with recurring operating income growing faster than sales€ millionexcept % Q12024 Q12025 Reported...

23 April 2025: Borregaard ASA (”Borregaard”, OSE ticker: BRG) Presentation of Q1 2025 results Borregaard will report first quarter 2025 results on Wednesday 30 April 2025 at 07:00 CEST. A stock exchange announcement will be made. A press release, the quarterly report and a presentation will be made available on https://www.borregaard.com/investors/. A presentation of the first quarter 2025 results will also be held at 08:30 CEST at SEB, Filipstadveien 10, Bygg B, Oslo. Attendance in person is possible. The presentation can be followed live on web-TV at https://www.borregaard.com/investors/. It will be possible to ask questions via the web. All presentations will be held in English. For more information about Borregaard ASA, please visit https://www.borregaard.com/. Contact:Lotte Kvinlaug, Investor Relations Officer, +47 922 86 909 This...

First quarterOrder intake for the first quarter increased by 97% to SEK 930 m (473). Organically, order intake increased by 12%, acquired growth was 89% and currency effects impacted by -4% Net sales increased by 44% to SEK 890 m (616). Organically, net sales decreased by 17%. Acquired growth was 59% and currency translations impacted by 2% Adjusted EBIT reached SEK 218 m (137), equal to a 24.5% (22.2) adjusted operating margin EBIT reached SEK 175 m (130), equal to a 19.6% (21.1) operating margin Adjusted profit after tax totaled SEK 159 m (113) and adjusted basic earnings per share was SEK 3.17 (2.43) Profit after tax totaled SEK 115 m (107) and basic earnings per share was SEK 2.29 (2.28) Cash flow from operating activities amounted to SEK 187 m (58) New organizational structure from 2025 to strengthen customer focus and cross-sellingLast...

Fort Lawn, SC, April 22, 2025 (GLOBE NEWSWIRE) — Northann Corp. (“Northann” or the “Company”) (NYSE American: NCL), a company specializing in 3D printing and manufacturing solutions, announced today that on April 16, 2025, the Company received a written notice from NYSE Regulation (the “Filing Delinquency Notification”) stating that the Company is not in compliance with the continued listing standards of the NYSE American LLC (“NYSE American”, or the “Exchange”). Specifically, the Company has not met the requirements set forth in Sections 134 and 1101 of the NYSE American Company Guide due to its delayed filings of the Form 10-K for the year ended December 31, 2024 (the “Delinquent Report”) by the filing due date of April 15, 2025 (the “Filing Delinquency”). Reference is made to the Company’s Notification of Late Filing on Form...